Deep Dive: Page 3

Industry insights from our journalists


  • story image
    Image attribution tooltip
    Yujin Kim / BioPharma Dive

    Will a big needle burst the NASH bubble?

    With less invasive tests still a few years off, doctors worry liver biopsies will limit access to the initial wave of NASH drugs — if any make it to market. 

    Jacob Bell • May 14, 2019
  • story image
    Image attribution tooltip
    Novartis

    Pharma, late to digital game, rushes to catch up

    In the past two years, six of the largest pharmas appointed chief digital or information officers to top management for the first time, a signal of growing industry interest in revamping how it does business.

    Ned Pagliarulo • May 13, 2019
  • story image
    Image attribution tooltip
    Getty Images

    Biopharma happily takes the tax cuts, but the jobs are harder to find

    The tax burden of U.S.-based drugmakers shrank by nearly one-quarter following the 2017 Republican tax bill, but jobs edged up only slightly, a BioPharma Dive analysis found.

    Jonathan Gardner • May 9, 2019
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive, photo from Incyte

    Unblinded: Hervé​ Hoppenot on solving Incyte's 'single asset syndrome'

    Last April, a closely watched study of an Incyte cancer drug failed, sending the biotech back to the drawing board. This year could help answer what's next. 

    Ned Pagliarulo • April 10, 2019
  • story image
    Image attribution tooltip
    Getty Images

    Aducanumab's failure puts pressure on field to look beyond amyloid

    "At this point, we've done the right experiment and the hypothesis didn't hold true," said Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation.

    Ned Pagliarulo • March 22, 2019
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive; image from the Milken Institute

    Unblinded: Scott Gottlieb on biosimilars' precarious moment and the gene therapy boom

    The outgoing FDA chief spoke with BioPharma Dive a day before his surprise resignation, detailing how drugmaker "shenanigans" have evolved and weighing in on gene therapy's inflection point.

    Andrew Dunn • March 12, 2019
  • story image
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Pharma is shuffling around jobs, but a skills gap threatens the process

    Drugmakers have found difficulty luring employees who can work with the latest technologies away from the likes of Amazon and Google, for instance. 

    Jacob Bell • Feb. 4, 2019
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    A flashy 2019 start to pharma M&A, but will it last?

    Recent high-profile acquisitions don't fully clear up what the buyer's market will look like in an expected bumper year for dealmaking.

    Jacob Bell • Jan. 22, 2019
  • How a 'regulatory dead zone' may be holding up copycat insulin

    The FDA has talked up biosimilars' potential impact on the insulin market, but changing regulations have complicated matters for would-be competitors.

    Andrew Dunn • Jan. 14, 2019
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    At JPM, the NASH flood gates start to crack

    Multiple late-stage results are slated for 2019, bringing to the forefront a question of how battle lines will be drawn across the market.

    Jacob Bell • Jan. 11, 2019
  • story image
    Image attribution tooltip
    Getty Images

    Hunting productivity, drugmakers pitch new 'pillars' of R&D

    By some measures, returns on R&D have fallen to decade lows. Pharmas and biotechs, however, argue new technologies could open faster paths to market. 

    Ned Pagliarulo • Jan. 11, 2019
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    3 questions leaving ASH

    Like many a medical meeting, ASH showcased data that — while promising — also offers as many questions as answers.

    Jacob Bell • Dec. 5, 2018
  • story image
    Image attribution tooltip
    Jacob Bell / BioPharma Dive

    At ASH, bispecific cancer therapies make a mark

    The therapies work to guide tumor-fighting immune cells to target cancerous invaders. Research at ASH suggests they could be another avenue of attack in immuno-oncology.

    Ned Pagliarulo and Jacob Bell • Dec. 5, 2018
  • Executive of the Year: Emma Walmsley, GlaxoSmithKline

    Since taking the helm, Walmsley has launched an R&D restructure, shaken up GSK's top leadership and reset a corporate strategy that's failed to deliver industry-leading growth.

    Ned Pagliarulo • Dec. 3, 2018
  • story image
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Memorial Sloan Kettering scandal raises questions for pharma's biggest corporate boards

    A review of corporate board membership found about two-thirds of the largest drugmakers had at least one director who also had a leadership role in a nonprofit healthcare organization.

    Andrew Dunn • Nov. 29, 2018
  • story image
    Image attribution tooltip
    Gilead Sciences Inc.

    Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.

    The therapy lags its competitors in getting to market, but clinical data could make filgotinib stand out. How much would a late arrival hurt its prospects?

    Andrew Dunn • Nov. 26, 2018
  • story image
    Image attribution tooltip
    Yugin Kim / BioPharma Dive

    Red pill or blue? It could be a billion-dollar decision

    Viagra and Nexium ​underscore how marketers and manufacturers can use color to make a drug franchise more successful.

    Jacob Bell • Oct. 29, 2018
  • story image
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive

    First Amendment takes center stage in DTC price fight

    A string of court decisions have bolstered commercial speech rights for industry. The Trump administration's push to require prices in TV ads could become the next legal battleground.

    Andrew Dunn • Oct. 22, 2018
  • story image
    Image attribution tooltip
    Yujin Kim / BioPharma Dive

    Pharma's slow embrace of continuous manufacturing

    On the whole, drugmakers remain wedded to traditional production methods that have served for decades. Some, however, are shifting to newer technology.

    Ned Pagliarulo • Sept. 24, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    For CDMOs, continuous manufacturing isn't an 'if,' but a 'how'

    Contract services providers are receiving more interest from drugmakers keen on the technology's potential cost-savings and better efficiency.

    Jacob Bell • Sept. 24, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    As FDA and pharma warm to continuous manufacturing, generics stay skeptical

    Generics companies worry continuous manufacturing could become another tool for branded drugmakers to protect their products.

    Andrew Dunn • Sept. 24, 2018
  • FDA confronts its limits in push on drug pricing

    Legally, regulating prices is outside of the FDA's purview. But that hasn't stopped Scott Gottlieb from taking a more vocal approach to the hot-button issue than past FDA chiefs.

    Ned Pagliarulo • Aug. 27, 2018
  • story image
    Image attribution tooltip
    Kendall Davis / BioPharma Dive

    FDA ups the ante for copycats, antibiotics, orphan drugs. But is it working?

    Regulators are using incentives to spur development of much-needed drugs. The results so far have been mixed.

    Jacob Bell • Aug. 27, 2018
  • story image
    Image attribution tooltip
    Credit: Andrew Propp, FDA / Edited by BioPharma Dive

    How Scott Gottlieb is upending FDA communication, one tweet at a time

    The FDA commissioner has relentlessly pumped out tweets, statements and more. But how has that affected FDA communications and the agency overall?

    Andrew Dunn • Aug. 27, 2018
  • story image
    Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Seeking to adopt AI, drugmakers search for right mix of talent

    AI holds promise as a powerful new tool in the hunt for new drugs. Yet building a team that blends tried-and-true methods with AI remains a challenge.

    Ned Pagliarulo • July 23, 2018